The features of CTI therapy are as follows: (1) since NPrCAP is a tyrosinase-specific substrate, it is selectively incorporated into melanocytes and melanoma cells through vesicular transport, and adverse effects are therefore expected to be minimal [10,13] and (2) the generation of heat by magnetite nanoparticles with AMF induces not only heat-mediated cell death but also an immune reaction, due to the generation of heat shock proteins (HSPs) [18,20]. Here, TYR is linked to melanoma.